Original Article

You have full text access to this OnlineOpen article

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma

  1. Gary H. Lyman M.D., M.P.H.1,†,‡,*,
  2. David J. Delgado Ph.D., M.P.H.2,§

Article first published online: 3 NOV 2003

DOI: 10.1002/cncr.11827

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2402–2409, 1 December 2003

Additional Information

How to Cite

Lyman, G. H. and Delgado, D. J. (2003), Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer, 98: 2402–2409. doi: 10.1002/cncr.11827

Author Information

  1. 1

    Department of Medicine, University of Rochester School of Medicine and Dentistry and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York

  2. 2

    Health, Economics, and Outcomes Research, Amgen, Inc., Thousand Oaks, California

  1. †

    Fax: (585) 506-1885

  2. ‡

    Dr. Lyman is a member of the Speaker's Bureau for Amgen, Inc., OrthoBiotech, and Aventis and has received grant support from Amgen, Inc., OrthoBiotech, and GlaxoSmithKline.

  3. §

    Dr. Delgado is employed by and owns stock in Amgen, Inc.

*University of Rochester Medical Center, 601 Elmwood Avenue, P.O. Box 704, Rochester, NY 14642

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 3 NOV 2003
  3. Manuscript Accepted: 3 SEP 2003
  4. Manuscript Revised: 30 AUG 2003
  5. Manuscript Received: 15 JUN 2003

Funded by

  • Amgen, Inc., Thousand Oaks, CA

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (389K)

REFERENCES

  • 1
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 1002–1006.
  • 2
    Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346: 235–242.
  • 3
    Pavlovsky S, Santarelli MT, Erazo A, et al. Results of a randomized study of previously untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol. 1992; 3: 205–209.
  • 4
    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164–170.
  • 5
    Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A: 319–324.
  • 6
    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002; 112: 406–411.
  • 7
    Weiner N, Fridman M, Steinberg D, et al. A model to predict chemotherapy related neutropenic events in intermediate and high grade lymphoma (IHL) patients [abstract]. Blood. 1998; 92: 88a.
  • 8
    Morrison V, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001; 2: 47–56.
  • 9
    Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado D, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 2069–2076.
  • 10
    Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdukul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2000; 37: 351–360.
  • 11
    Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998; 16: 2065–2069.
  • 12
    [No authors listed]. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982; 9: 2112–2135.
  • 13
    Carbone PP, Kaplan H, Musshoff K, Smithers DW. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861.
  • 14
    Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 1281–1288.
  • 15
    Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y. Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1988; 24: 533–538.
  • 16
    Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1988.
  • 17
    Kwak LW, Halpen J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963–977.
  • 18
    Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group Experience. J Clin Oncol. 1986; 4: 295–305.
  • 19
    Chrischilles EA, Link BK, Scott SJ, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control. In press.
  • 20
    Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony–stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control. 2002; 9: 203–211.
  • 21
    Kuderer NM, Cosler L, Crawford J, et al. Cost and mortality associated with febrile neutropenia in adult cancer patients [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 250a.
View Full Article (HTML) Get PDF (389K)